Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hypertension

  Free Subscription


Articles published in Eur Heart J

Retrieve available abstracts of 68 articles:
HTML format
Text format



Single Articles


    June 2018
  1. ABELL JG, Kivimaki M, Dugravot A, Tabak AG, et al
    Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension.
    Eur Heart J. 2018 Jun 12. pii: 5032485. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  2. BURNIER M
    Hypertension Guidelines.
    Eur Heart J. 2018;39:908-910.
    PubMed     Text format    


    January 2018
  3. MEHLUM MH, Liestol K, Kjeldsen SE, Julius S, et al
    Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
    Eur Heart J. 2018 Jan 20. pii: 4815726. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. MESSERLI FH, Rimoldi SF, Bangalore S
    Changing definition of hypertension in guidelines: how innocent a number game?
    Eur Heart J. 2018 Jan 9. pii: 4794716. doi: 10.1093.
    PubMed     Text format    


    December 2017
  5. GALIE N, Manes A, Dardi F, Palazzini M, et al
    Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease.
    Eur Heart J. 2017 Dec 27. pii: 4780182. doi: 10.1093.
    PubMed     Text format    


  6. BERMEJO J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, et al
    Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
    Eur Heart J. 2017 Dec 21. pii: 4769387. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  7. LUSCHER TF
    From 'essential' hypertension to intensive blood pressure lowering: the pros and cons of lower target values.
    Eur Heart J. 2017;38:3258-3271.
    PubMed     Text format    


    October 2017
  8. RUIZ-HURTADO G, Ruilope LM
    Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension.
    Eur Heart J. 2017 Oct 20. doi: 10.1093.
    PubMed     Text format    


  9. LUSCHER TF
    Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles.
    Eur Heart J. 2017;38:2857-2859.
    PubMed     Text format    


    September 2017
  10. SCHMIEDER RE, Wagner F, Mayr M, Delles C, et al
    The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Eur Heart J. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. AOKI T, Sugimura K, Tatebe S, Miura M, et al
    Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications.
    Eur Heart J. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. KIVIMAKI M, Nyberg ST, Batty GD, Kawachi I, et al
    Long working hours as a risk factor for atrial fibrillation: a multi-cohort study.
    Eur Heart J. 2017;38:2621-2628.
    PubMed     Text format     Abstract available


    June 2017
  13. WEATHERALD J, Sitbon O, Humbert M
    Validation of a risk assessment instrument for pulmonary arterial hypertension.
    Eur Heart J. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format    


  14. KYLHAMMAR D, Kjellstrom B, Hjalmarsson C, Jansson K, et al
    A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension.
    Eur Heart J. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  15. PATEL RS, Masi S, Taddei S
    Understanding the role of genetics in hypertension.
    Eur Heart J. 2017 May 25. doi: 10.1093.
    PubMed     Text format    


  16. MAHFOUD F, Schmieder RE, Azizi M, Pathak A, et al
    Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.
    Eur Heart J. 2017 May 5. doi: 10.1093.
    PubMed     Text format    


    April 2017
  17. NIIRANEN TJ, McCabe EL, Larson MG, Henglin M, et al
    Risk for hypertension crosses generations in the community: a multi-generational cohort study.
    Eur Heart J. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. LUSCHER TF
    From systemic and pulmonary hypertension to heart failure: novel drugs and devices.
    Eur Heart J. 2017;38:1087-1090.
    PubMed     Text format    


  19. FUKS KB, Weinmayr G, Basagana X, Gruzieva O, et al
    Long-term exposure to ambient air pollution and traffic noise and incident hypertension in seven cohorts of the European study of cohorts for air pollution effects (ESCAPE).
    Eur Heart J. 2017;38:983-990.
    PubMed     Text format     Abstract available


    March 2017
  20. VAN EMPEL V, Knackstedt C, van Paassen P, Brunner-La Rocca HP, et al
    Just air good enough in pulmonary hypertension?
    Eur Heart J. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format    


  21. ULRICH S, Hasler ED, Saxer S, Furian M, et al
    Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial.
    Eur Heart J. 2017 Mar 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. VAN GELDER IC, Healey JS, Crijns HJ, Wang J, et al
    Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.
    Eur Heart J. 2017 Mar 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  23. GALIE N, Jansa P, Pulido T, Channick RN, et al
    SERAPHIN haemodynamic sub-study: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
    Eur Heart J. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. VAN DER FEEN DE, Bartelds B, de Boer RA, Berger RM, et al
    Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease.
    Eur Heart J. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. LYALL DM, Celis-Morales CA, Anderson J, Gill JM, et al
    Associations between single and multiple cardiometabolic diseases and cognitive abilities in 474 129 UK Biobank participants.
    Eur Heart J. 2017;38:577-583.
    PubMed     Text format     Abstract available


    January 2017
  26. MANCIA G, Oparil S, Whelton PK, McKee M, et al
    The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association.
    Eur Heart J. 2017 Jan 21. pii: ehw549. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. LIP GY, Coca A
    Hypertension and cardiac arrhythmias.
    Eur Heart J. 2017;38:223-225.
    PubMed     Text format    


  28. KROGAGER ML, Torp-Pedersen C, Mortensen RN, Kober L, et al
    Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data.
    Eur Heart J. 2017;38:104-112.
    PubMed     Text format    


  29. MAHFOUD F, Bakris G, Bhatt DL, Esler M, et al
    Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry.
    Eur Heart J. 2017;38:93-100.
    PubMed     Text format    


  30. PITT B, Rossignol P
    The association between serum potassium and mortality in patients with hypertension: 'a wake-up call'.
    Eur Heart J. 2017;38:113-115.
    PubMed     Text format    


  31. LUSCHER TF
    Hypertension: detection, mechanisms, outcomes, and treatment.
    Eur Heart J. 2017;38:67-69.
    PubMed     Text format    


    December 2016
  32. HOEPER MM, Lam CS, Vachiery JL, Bauersachs J, et al
    Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchdagger.
    Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093.
    PubMed     Text format    


    November 2016
  33. FRANKLIN SS, O'Brien E, Staessen JA
    Masked hypertension: understanding its complexity.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    October 2016
  34. BRUNO RM, Taddei S
    Renal denervation: a blunt weapon against isolated systolic hypertension?
    Eur Heart J. 2016.
    PubMed     Text format    


    July 2016
  35. MAHFOUD F, Bakris G, Bhatt DL, Esler M, et al
    Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  36. LOBO MD, Sobotka PA, Pathak A
    Interventional procedures and future drug therapy for hypertension.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  37. PITT B, Rossignol P
    The association between serum potassium and mortality in patients with hypertension: 'a wake-up call'.
    Eur Heart J. 2016.
    PubMed     Text format    


    May 2016
  38. LUSCHER TF
    Frontiers in congenital heart disease: pulmonary hypertension, heart failure, and arrhythmias.
    Eur Heart J. 2016;37:1407-9.
    PubMed     Text format    


    April 2016
  39. KROGAGER ML, Torp-Pedersen C, Mortensen RN, Kober L, et al
    Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    March 2016
  40. LUSCHER TF
    Update on hypertension: target blood pressure, comorbidities, and outcome.
    Eur Heart J. 2016;37:921-3.
    PubMed     Text format    


  41. MUNZEL T, Gori T, Schmidt F
    CardioPulse. Noise pollution and arterial hypertension.
    Eur Heart J. 2016;37:933-6.
    PubMed     Text format    


  42. EWEN S, Zivanovic I, Bohm M, Mahfoud F, et al
    CardioPulse. Catheter-based renal denervation for hypertension treatment: update 2015.
    Eur Heart J. 2016;37:930-3.
    PubMed     Text format    


  43. LOBO MD, Paton JF
    CardioPulse. The use of devices to treat hypertension.
    Eur Heart J. 2016;37:927-9.
    PubMed     Text format    


  44. OPARIL S
    CardioPulse. The SPRINT trial results.
    Eur Heart J. 2016;37:924-7.
    PubMed     Text format    


  45. LUSCHER TF, Sudano I
    SPRINT: the race for optimal blood pressure control.
    Eur Heart J. 2016;37:937-41.
    PubMed     Text format    


  46. NISHIO M, Hirooka K, Doi Y
    Chinese herbal drug natural indigo may cause pulmonary artery hypertension.
    Eur Heart J. 2016.
    PubMed     Text format    


  47. STOEKENBROEK RM, Boekholdt SM, Luben R, Hovingh GK, et al
    Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study.
    Eur Heart J. 2016;37:880-9.
    PubMed     Text format     Abstract available


    February 2016
  48. HAN QJ, Contijoch F, Forfia PR, Han Y, et al
    Four-dimensional flow magnetic resonance imaging visualizes drastic changes in the blood flow in a patient with chronic thromboembolic pulmonary hypertension after pulmonary thromboendarterectomy.
    Eur Heart J. 2016.
    PubMed     Text format    


  49. SKRIDE A, Sablinskis K, Klepetko W, Lang I, et al
    Choriocarcinoma mimicking chronic thromboembolic pulmonary hypertension.
    Eur Heart J. 2016.
    PubMed     Text format    



  50. Erratum to 'Heme oxygenase-1 suppresses a pro-inflammatory phenotype in monocytes and determines endothelial function and arterial hypertension in mice and humans'.
    Eur Heart J. 2016.
    PubMed     Text format    


  51. DIENER HC, Aisenberg J, Ansell J, Atar D, et al
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    January 2016
  52. CHIBANA H, Tahara N, Itaya N, Sasaki M, et al
    Optical frequency-domain imaging and pulmonary angioscopy in chronic thromboembolic pulmonary hypertension.
    Eur Heart J. 2016.
    PubMed     Text format    


  53. LUSCHER TF
    Pulmonary hypertension, gender issues, and quality of care.
    Eur Heart J. 2016;37:1-3.
    PubMed     Text format    


  54. HUMBERT M, Galie N
    The Ten Commandments for 2015 European Society of Cardiology-European Respiratory Society Guidelines on Pulmonary Hypertension.
    Eur Heart J. 2016;37:5.
    PubMed     Text format    


  55. REGITZ-ZAGROSEK V, Oertelt-Prigione S, Prescott E, Franconi F, et al
    Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes.
    Eur Heart J. 2016;37:24-34.
    PubMed     Text format    


    November 2015
  56. MANCIA G, Kjeldsen SE, Zappe DH, Holzhauer B, et al
    Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    August 2015
  57. PERRONE-FILARDI P, Paolillo S, Costanzo P, Savarese G, et al
    The role of metabolic syndrome in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    June 2015
  58. GUTIERREZ A, Bhatt DL
    Medical management of peripheral artery disease in diabetes mellitus.
    Eur Heart J. 2015;36:1494-5.
    PubMed     Text format    


    May 2015
  59. HILFIKER-KLEINER D, Haghikia A, Nonhoff J, Bauersachs J, et al
    Peripartum cardiomyopathy: current management and future perspectives.
    Eur Heart J. 2015;36:1090-7.
    PubMed     Text format     Abstract available


  60. KARANASOS A, Van Mieghem NM, Regar E, Daemen J, et al
    Serial imaging observations of vascular healing in a denervation-induced renal artery dissection.
    Eur Heart J. 2015;36:1040.
    PubMed     Text format    


    April 2015
  61. LUSCHER TF
    An update on heart failure and peripheral arterial disease.
    Eur Heart J. 2015;36:885-7.
    PubMed     Text format    


    March 2015
  62. RAM VS
    CardioPulse: the burden of cardiovascular disease in India.
    Eur Heart J. 2015;36:704-5.
    PubMed     Text format    



  63. Renal denervation more successful when it includes accessory arteries.
    Eur Heart J. 2015;36:536.
    PubMed     Text format    


  64. MASON E, Tofield A
    New analysis of the SYMPLICITY HTN-3 trial.
    Eur Heart J. 2015;36:535.
    PubMed     Text format    


  65. TAYLOR J
    European Society of Cardiology launches Council on Hypertension.
    Eur Heart J. 2015;36:532-3.
    PubMed     Text format    


  66. MESSERLI FH, Bangalore S, Schmieder RE
    Wilder's principle: pre-treatment value determines post-treatment response.
    Eur Heart J. 2015;36:576-9.
    PubMed     Text format    


    February 2015
  67. SCHNOHR P, Marott JL, Kristensen TS, Gyntelberg F, et al
    Ranking of psychosocial and traditional risk factors by importance for coronary heart disease: the Copenhagen City Heart Study.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    January 2015
  68. JACKSON CE, Castagno D, Maggioni AP, Kober L, et al
    Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: